PHARMAC responds on salbutamol
Metcalfe, S.; Moodie, P.; Davies, A.; McNee, W.; Dougherty, S.
New Zealand Medical Journal 118(1221): U1644
2005
ISSN/ISBN: 1175-8716 PMID: 16138178 Document Number: 590206
Document emailed within 1 workday
Related Documents
Metcalfe, S.; Wilkinson, T.; Rasiah, D. 2006: PHARMAC responds on agents to prevent osteoporotic fractures New Zealand Medical Journal 119(1230): U1895Guarnaccia, S.; Pasquali, M.; Acerbis, F.; Pedrali, M.; Duse, M.; Ugazio, A.G. 1990: Clinico-functional evaluation of flunisolide + salbutamol combination (VAL 679/A) vs salbutamol in pediatric patients Minerva Pediatrica 42(6): 237-242
Chhabra, S.K. 1994: A comparison of inhaled salbutamol with a combination of salbutamol and beclomethasone dipropionate in moderately severe asthma Indian Journal of Chest Diseases and Allied Sciences 36(3): 119-124
Krasnowska, M.; Liebhart, E.; Małolepszy, J. 1994: Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil Pneumonologia i Alergologia Polska 62(7-8): 365-369
Prabhu Shankar, S.; Chandrashekharan, S.; Bolmall, C.S.; Baliga, V. 2010: Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study Journal of the Indian Medical Association 108(5): 313-314; 316-318, 320
Bennett, W.; McNee, W. 1998: PHARMAC and statins New Zealand Medical Journal 111(1077): 439-440
Grocott, R.; Metcalfe, S.; Moodie, P. 2006: PHARMAC and erythropoietin for cancer patients New Zealand Medical Journal 119(1236): U2039
Haddad, P. 1999: PHARMAC complicates treatment of glaucoma New Zealand Medical Journal 112(1099): 434
Baber, W.J.; Neeff, M. 2008: Ciproxin HC eardrops application for funding--and response from PHARMAC New Zealand medical journal 121(1281): 111-2; author reply 112-4
Metcalfe, S.; Moodie, P.; McNee, W. 2005: PHARMAC and tobacco control in New Zealand: two licensed funded options are already available New Zealand medical journal 118(1217): U1544; author reply U1544; discussion U1544
Milne, R.; Wonder, M. 2011: Response to PHARMAC on Access to new medicines in New Zealand compared to Australia New Zealand Medical Journal 124(1347): 91-93
Grocott, R.; Metcalfe, S. 2012: PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric New Zealand Medical Journal 125(1358): 89-90
Grocott, R.; Metcalfe, S.; Alexander, P.; Werner, R. 2013: Assessing the value for money of pharmaceuticals in new Zealand--PHARMAC's approach to cost-utility analysis New Zealand Medical Journal 126(1378): 60-73
Blakeney, B. 2002: ANA responds to outrageous Op-ed Alabama Nurse 29(3): 22
Dilsaver, S.C. 1990: Winter depression responds to an antidepressant American Family Physician 42(1): 41-42
Timmerman, G.L. 2004: College responds to young surgeons asking, "What's in it for me?" Bulletin of the American College of Surgeons 89(10): 22-24
2005: Board responds to legislative recommendations Journal of the American Veterinary Medical Association 227(3): 367-368
Freiberger, J.; Coulombe, K.; Suliman, H.; Carraway, M.; Piantadosi, C. 2004: Superoxide dismutase responds to hyperoxia in rat hippocampus Undersea and Hyperbaric Medicine: Journal of the Undersea and Hyperbaric Medical Society Inc 31(2): 227-232
Wallace, J.D. 1974: CMA responds to challenge, helps shape change Canadian Medical Association Journal 111(9): 977
Wood, P.G. 2006: Reader responds to "could computerization harm patient safety?" Medgenmed: Medscape General Medicine 8(3): 53